Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men

Neuropsychopharmacology

Volumn 30, Issue 9, 2005, Pages 1751-1763

  Mendelson, Jack H ^a,b   Sholar, Michelle B ^a   Goletiani, Nathalie ^a   Siegel, Arthur J ^a   Mello, Nancy K ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

ACTH; Cigarette smoking; Cortisol; DHEA; Epinephrine; HPA axis; Nicotine

Indexed keywords

ADRENALIN; CORTICOTROPIN; HYDROCORTISONE; NICOTINE; PRASTERONE; NICOTINIC AGENT;

ADRENALIN BLOOD LEVEL; ADULT; ARTICLE; BLOOD LEVEL; BRAIN REGION; CARDIOVASCULAR PARAMETERS; CIGARETTE SMOKING; CLINICAL ARTICLE; CORRELATION ANALYSIS; CORTICOTROPIN BLOOD LEVEL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG DEPENDENCE; HORMONE BLOOD LEVEL; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MOOD; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TOBACCO DEPENDENCE; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME; AFFECT; ANALYSIS OF VARIANCE; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART RATE; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNORADIOMETRIC ASSAY; METHODOLOGY; PAIN ASSESSMENT; PATHOPHYSIOLOGY; SMOKING; TIME;

ADRENOCORTICOTROPIC HORMONE; ADULT; AFFECT; ANALYSIS OF VARIANCE; BLOOD PRESSURE; DEHYDROEPIANDROSTERONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; EPINEPHRINE; HEART RATE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNORADIOMETRIC ASSAY; MALE; NICOTINE; NICOTINIC AGONISTS; PAIN MEASUREMENT; PITUITARY-ADRENAL SYSTEM; SMOKING; TIME FACTORS;

EID: 27744439807     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300753     Document Type: Article

References (95)

1. Abreu ME, Bigelow GE, Fleisher L (2001). Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology 154: 76-84.
2. al'Absi M, Hatsukami DK, Davis GL, Wittmers LE (2004). Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol Depend 73: 267-278.
3. al'Absi M, Wittmers LE, Erickson J, Hatsukami DK, Crouse B (2003). Attenuated adrenocortical and blood pressure responses to psychological stress in ad libitum and abstinent smokers. Pharmacol Biochem Behav 74: 401-410.
4. APA (1994). Diagnostic and Statistical Manual of Mental Disorders 4th edn. American Psychiatric Association: Washington, DC. 886pp.
5. Ayala AR, Pushkas J, Higley JD, Ronsaville D, Gold PW, Chrousos GP et al (2004). Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. J Clin Endocrinol Metab 89: 5729-5737.
6. Balster RL, Schuster CR (1973). Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 20: 119-129.
7. Baron JA, Comi RJ, Cryns V, Brinck-Johnsen T, Mercer NG (1995). The effect of cigarette smoking on adrenal cortical hormones. J Pharmacol Exp Ther 272: 151-155.
8. Benowitz NL (1996). Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmcol Toxicol 36: 597-613.
9. Benowitz NL (2001). Compensatory smoking of low-yield cigarettes. In: Risks Associated with Smoking Cigarettes with Low Machine-Measured Yields of Tar and Nicotine. Smoking and Tobacco Control Monograph No. 13. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute, October 2001, Bethesda, MD. NIH Pub. No. 02-5074, pp 39-63.
10. Broadbear JH, Winger G, Cicero TJ, Woods JH (1999a). Effects of self-administered cocaine on plasma adrenocorticotropic hormone and cortisol in male rhesus monkeys. J Pharmacol Exp Ther 289: 1641-1647.
11. Broadbear JH, Winger G, Woods JH (1999b). Cocaine-reinforced responding in rhesus monkeys: pharmacological attenuation of the hypothalamic-pituitary- adrenal axis response. J Pharmacol Exp Ther 290: 1347-1355.
12. Butschky MF, Bailey D, Henningfield JE, Pickworth WB (1995). Smoking without nicotine delivery decreases withdrawal in 12-h abstinent smokers. Pharmacol Biochem Behav 50: 91-96.
13. CDC (2000). Declines in lung cancer rates - California, 1988-1997. Morbidity Mortality Weekly Rep 49: 1066-1069.
14. CDC (2001). Women and smoking: a report of the Surgeon General. National Center for Chronic Disease Prevention and Prevention and Health Promotion. Office on Smoking and Health, Washington, DC. 675pp.
15. CDC (2004). Adult cigarette smoking in the United States: current estimates. National Center for Chronic Disease Prevention and Health Promotion. Tobacco Information and Prevention Source (TIPS), Vol 15, pp 20-58.
16. Coiro V, Vescovi PP (1999). Effect of cigarette smoking on ACTH/cortisol secretion in alcoholics after short- and medium-term abstinence. Alcohol Clin Exp Res 23: 1515-1518.
17. Contoreggi C, Herning RI, Na P, Gold PW, Chrousos G, Negro PJ et al (2003). Stress hormone responses to corticotropin-releasing hormone in substance abusers with severe comorbid psychiatric disease. Biol Psychiatry 54: 873-878.
18. Corrigall WA (1999). Nicotine self-administration in animals as a dependence model. Nicotine Tobacco Res 1: 11-20.
19. Cryer PE, Haymond MW, Santiago JV, Shah SD (1976). Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 295: 573-577.
20. del Arbol JL, Munoz JR, Ojeda L, Cascales AL, Irles JR, Mianda MT et al (2000). Plasma concentrations of beta-endophin in smokers who consume different numbers of cigarettes per day. Pharmacol Biochem Behav 67: 25-28.
21. Donny EC, Caggiula AR, Mielke MM, Booth S, Gharib MA, Hoffman A et al (1999). Nicotine self-administration in rats on a progressive ratio schedule of reinforcement. Psychopharmacology (Berl) 147: 135-142.
22. Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB (1994). The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 79: 1310-1316.
23. Fu Y, Matta SG, Gao W, Brower VG, Sharp BM (2000). Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area. J Pharmacol Exp Ther 294: 458-465.
24. Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL (2000). Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38: 432-437.
25. Goeders NE (1997). A neuroendocrine role in cocaine reinforcement. Psychoneuroendocrinology 22: 237-259.
26. Goeders NE (2002a). The HPA axis and cocaine reinforcement. Psychoneuroendocrinology 27: 13-33.
27. Goeders NE (2002b). Stress and cocaine addiction. J Pharmacol Exp Ther 301: 785-789.
28. Goeders NE, Guerin GF (1996). Role for corticosterone in intravenous cocaine self-administration in rats. Neuroendocrinology 64: 337-348.
29. Goeders NE, Guerin GF (2000). Effects of the CRH receptor antagonist CP-154,526 on intravenous cocaine self-administration in rats. Neuropsychopharmacology 23: 577-586.
30. Goldberg SR, Spealman RD, Goldberg DM (1981). Persistent behavior at high rates maintained by intravenous self-administration of nicotine. Science 214: 573-575.
31. Gossain VV, Sherma NK, Srivastava L, Michelakis AM, Rovner DR (1986). Hormonal effects of smoking - II: effects on plasma cortisol, growth hormone, and prolactin. Am J Med Sci 291: 325-327.
32. Gourlay SG, Benowitz NL (1997). Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 62: 453-463.
33. Grammatopoulos DK, Chrousos GP (2002). Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab 13: 436-444.
34. Griffiths RR, Henningfield JE, Bigelow GE (1982). Human cigarette smoking: manipulation of number of puffs per bout, interbout interval and nicotine dose. J Pharmacol Exp Ther 220: 256-265.
35. Gross J, Lee J, Stitzer ML (1997). Nicotine-containing versus de-nicotinized cigarettes: effects on craving and withdrawal. Pharmacol Biochem Behav 57: 159-165.
36. Habib KE, Weld KP, Rice KC, Pushkos J, Champoux M, Listwak S et al (2000). Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci USA 97: 6079-6084.
37. Harvey DM, Yasar S, Heishman SJ, Panlilio LV, Henningfield JE, Goldberg SR (2004). Nicotine serves as an effective reinforcer of intravenous drug-taking behavior in human cigarette smokers. Psychopharmacology (Berl) 175: 134-142.
38. Heinrichs SC, Koob GF (2004). Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther 311: 427-440.
39. Henningfield JE, Goldberg SR (1983). Control of behavior by intravenous nicotine injections in human subjects. Pharmacol Biochem Behav 19: 1021-1026.
40. Henningfield JE, Schuh LM, Jarvik ME (1995). Pathophysiology of tobacco dependence. In: Bloom FE, Kupfer DJ (eds). Psychopharmacology. The Fourth Generation of Progress. Raven Press: New York. pp 1715-1729.
41. Iranmanesh A, Lizarralde G, Short E, Veldhuis JD (1990). Intensive venous sampling paradigms disclose high frequency adrenocorticotropin release episodes in normal men. J Clin Endocrinol Metab 71: 1276-1283.
42. Jacob P, Wu S, Yu L, Benowitz NL (2000). Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry. J Pharmaceut Biomed Anal 23: 653-661.
43. Jaffe JH (1990). Tobacco smoking and nicotine dependence. In: Wonnacott S, Russell MAH, Stolerman IP (eds). Nicotine Psychopharmacology Molecular, Cellular, and Behavioural Aspects. Oxford University Press: New York. pp 1-37.
44. Jones HE, Garrett BE, Griffiths RR (1999). Subjective and physiological effects of intravenous nicotine and cocaine in cigarette smoking cocaine abusers. J Pharmacol Exp Ther 288: 188-197.
45. Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97-129.
46. Kuhar MJ, Ritz MC, Boja JW (1991). The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci 14: 299-302.
47. Mantsch JR, Schlussman SD, Ho A, Kreek MJ (2000). Effects of cocaine self-administration on plasma corticosterone and prolactin in rats. J Pharmacol Exp Ther 294: 239-247.
48. Marinelli M, Piazza PV (2002). Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci 16: 387-394.
49. Matta SG, Foster CA, Sharp BM (1993a). Nicotine stimulates the expression of cFos protein in the parvocellular paraventricular nucleus and brainstem catecholaminergic regions. Endocrinology 132: 2149-2156.
50. Matta SG, Foster CA, Sharp BM (1993b). Selective administration of nicotine into catecholaminergic regions of rat brainstem stimulates adrencorticotropin secretion. Endocrinology 133: 2935-2942.
51. Matta SG, McAllen KM, Sharp BM (1990). Role of the fourth cerebroventricle in mediating rat plasma ACTH responses to intravenous nicotine. J Pharmacol Exp Ther 252: 623-630.
52. Matta SG, Valentine JD, Sharp BM (1997). Nicotinic activation of CRH neurons in extrahypothalamic regions of the rat brain. Endocrine 7: 245-253.
53. Matta SG, Yitong F, Valentine JD, Sharp BM (1998). Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 23: 103-113.
54. MDPH (1998). Massachusetts Department of Public Health 1997 Cigarette Nicotine Disclosure Report as required by Massachusetts General Laws Chapter 307B, CMR 660,000, January 16, 1998.
55. Mello NK, Lukas SE, Mendelson JH (1985). Buprenorphine effects on cigarette smoking. Psychopharmacology 86: 417-424.
56. Mello NK, Mendelson JH (2002). Cocaine, hormones and behavior: clinical and preclinical studies. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds). Hormones, Brain and Behavior. Academic Press: New York, pp 665-745.
57. Mendelson JH, Mello NK, Sholar MB, Siegel AJ, Mutschler N, Halpern J (2002). Temporal concordance of cocaine effects on mood states and neuroendocrine hormones. Psychoneuroendocrinology 27: 71-82.
58. Mendelson JH, Sholar MB, Goletiani NV, Siegel AJ, Mello NK (2004). Menstrual cycle phase influences the effects of cigarette smoking on mood states and the HPA axis. ACNP 43rd Annual Meeting, San Juan, PR, December 2004. Neuropsychopharmacology 29: S138.
59. Mendelson JH, Sholar MB, Mutschler NH, Jaszyna-Gasior M, Goletiani NV, Siegel AJ et al (2003). Effects of intravenous cocaine and cigarette smoking on luteinizing hormone, testosterone and prolactin in men. J Pharmacol Exp Ther 307: 339-348.
60. Mendelson JH, Teoh SK, Mello NK, Ellingboe J, Rhoades E (1992). Acute effects of cocaine on plasma adrenocorticotropic hormones, luteinizing hormone and prolactin levels in cocaine-dependent men. J Pharmacol Exp Ther 263: 505-509.
61. Morales AJ, Nolan JJ, Nelson JC, Yen SSC (1994). Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78: 1360-1367.
62. Mutschler NH, Stephen BJ, Teoh SK, Mendelson JH, Mello NK (2002). An inpatient study of the effects of buprenorphine on cigarette smoking in men concurrently dependent on cocaine and opioids. Nicotine Tobacco Res 4: 223-228.
63. Nemeroff CB (1996). The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Med Psychiatry 1: 336-342.
64. Nemeth-Coslett R, Griffiths RR (1984a). Determinants of puff duration in cigarette smokers: I. Pharmacol Biochem Behav 20: 965-971.
65. Nemeth-Coslett R, Griffiths RR (1984b). Determinants of puff duration in cigarette smokers: II. Pharmacol Biochem Behav 21: 903-912.
66. Perkins KA, Fonte C, Sanders M, Meeker J, Wilson A (2001). Threshold doses for nicotine discrimination in smokers and non-smokers. Psychopharmacology 155: 163-170.
67. Pickworth WB, Fant RV (1998). Endocrine effects of nicotine administration, tobacco and other drug withdrawal in humans. Psychoneuroendocrinology 23: 131-141.
68. Pickworth WB, Fant RV, Nelson RA, Rohrer MS, Henningfield JE (1999). Pharmacodynamic effects of new de-nicotinized cigarettes. Nicotine Tobacco Res 1: 357-364.
69. Pomerleau OF, Fertig JB, Seyler LE, Jaffe J (1983). Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology 81: 61-67.
70. Pomerleau OF, Flessland KA, Pomerleau CS, Hariharan M (1992). Controlled dosing of nicotine via an intranasal nicotine aerosol delivery device (INADD). Psychopharmacology 108: 519-526.
71. Robinson ML, Houtsmuller EJ, Moolchan ET, Pickworth WB (2000). Placebo cigarettes in smoking research. Exp Clin Psychopharmacol 8: 326-332.
72. 1Receptor-related neuroactive steroids modulate cocaine-induced reward. J Neurosci 23: 3572-3576.
73. Rose JE, Behm FM, Westman EC, Coleman RE (1999). Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction. Drug Alcohol Depend 56: 99-107.
74. Rose JE, Behm FM, Westman EC, Johnson M (2000). Dissociating nicotine and nonnicotine components of cigarette smoking. Pharmacol Biochem Behav 67: 71-81.
75. Sarnyai Z, Mello NK, Mendelson JH, Nguyen P, Erös-Sarnyai M (1995). Effects of cocaine and corticotropin-releasing factor (CRF) on pulsatile ACTH and cortisol release in ovariectomized rhesus monkeys. J Clin Endocrinol Metab 80: 2745-2751.
76. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St. Clair LS et al (2005). Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 62: 154-162.
77. Seyler Jr LE, Fertig J, Pomerleau O, Hunt D, Parker K (1984). The effects of smoking on ACTH and cortisol secretion. Life Sci 34: 57-65.
78. Seyler Jr LE, Pomerleau OF, Fertig JB, Hunt D, Parker K (1986). Pituitary hormone response to cigarette smoking. Pharmacol Biochem Behav 24: 159-162.
79. Shahan TA, Bickel WK, Madden GJ, Badger GJ (1999). Comparing the reinforcing efficacy of nicotine containing and de-nicotinized cigarettes: a behavioral economic analysis. Psychopharmacology 147: 210-216.
80. Sharp BM, Beyer HS (1986). Rapid desensitization of the acute stimulatory effects of nicotine on rat plasma adrenocorticotropin and prolactin. J Pharmacol Exp Ther 238: 486-491.
81. Sinha R (2001). How does stress increase risk of drug abuse and relapse? Psychopharmacology (Berl) 158: 343-359.
82. Sobel B-FX, Sigmon SC, Griffiths RR (2004). Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, but not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology 29: 991-1003.
83. Soria R, Stapleton JM, Gilson SF, Sampson-Cone A, Henningfield JE, London ED (1996). Subjective and cardiovascular effects of intravenous nicotine in smokers and non-smokers. Psychopharmacology (Berl) 128: 221-226.
84. Spark RF (2002). Dehydroepiandrosterone: a springboard hormone for female sexuality. Fertil Steril 77: S19-S25.
85. Spealman RD, Goldberg SR (1982). Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys. J Pharmacol Exp Ther 223: 402-408.
86. Spohr U, Hofmann K, Steck W, Harenberg J, Walter E, Hengen N et al (1979). Evaluation of smoking-induced effects on sympathetic, hemodynamic and metabolic variables with respect to plasma nicotine and COHb levels. Atherosclerosis 33: 271-283.
87. Teoh SK, Sarnyai Z, Mendelson JH, Mello NK, Springer SA, Sholar JW et al (1994). Cocaine effects on pulsatile secretion of ACTH in men. J Pharmacol Exp Ther 270: 1134-1138.
88. Tsigos C, Chrousos G (2002). Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 53: 865-871.
89. Tsigos C, Chrousos GP (1994). Physiology of the hypothalamic-pituitary- adrenal axis in health and dysregulation in psychiatric and autoimmune disorders. Endocrinol Metab Clin N Am 23: 451-466.
90. US Department of Health and Human Services (2004). The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, Atlanta, GA. 41pp.
91. Wakasa Y, Takada K, Yanagita T (1995). Reinforcing effect as a function of infusion speed in intravenous self-administration of nicotine in rhesus monkeys. Jpn J Psychopharmacol 15: 53-59.
92. Watkins SS, Koob GF, Markou A (2000). Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tobacco Res 2: 19-37.
93. Wilkins JN, Carlson HE, Van Vunakis H, Hill MA, Gritz E, Jarvik ME (1982). Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology (Berl) 78: 305-308.
94. Winternitz WW, Quillen D (1977). Acute hormonal response to cigarette smoking. J Clin Pharmacol 17: 389-397.
95. Yen SSC, Jaffe RB, Barbieri RL (1999). Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 4th edn. WB Saunders: Philadelphia. 839pp.